HEALTHEQUITY, INC. 8-K

What Happened

• HealthEquity, Inc. (HQY) filed an 8‑K reporting that on May 5, 2026 it signed amendments to employment agreements for six senior executives — CEO Scott Cutler, CFO James Lucania, Founder & Vice Chairman Dr. Stephen Neeleman, Michael Fiore, Sunil Rajasekar, and Delano Ladd — to provide enhanced severance benefits. The company’s Talent, Culture and Compensation Committee also approved new vesting terms on March 25, 2026 for equity awards granted after that date.

Key Details

• Amendments signed May 5, 2026 cover six executives: Scott Cutler (President & CEO), James Lucania (EVP & CFO), Stephen Neeleman (Founder & Vice Chairman), Michael Fiore (EVP & Chief Commercial Officer), Sunil Rajasekar (EVP & Chief Product & Strategy Officer), and Delano Ladd (EVP & General Counsel).
• Standard severance: 12 months of base salary on a termination by the company without cause or a resignation for good reason.
• CEO specifics: Cutler will receive, in addition to 12 months’ base pay, an amount equal to his target cash bonus for the year of termination; if termination occurs on or within 18 months after a change in control, he would receive 18 months’ base salary and 150% of his target cash bonus.
• Other executives: their amended agreements provide 12 months’ base salary, and they will receive an amount equal to their target cash bonus only if the termination occurs on or within 18 months following a change in control.
• Equity vesting (approved Mar 25, 2026 for awards granted after that date): time‑based RSUs that would vest within 12 months after a qualifying termination (company without cause or resignation for good reason, before a change in control) will vest and be settled at termination; performance PSUs will remain outstanding on a pro rata basis (by days employed) and be eligible to vest based on actual performance at the end of the performance period.
• Severance payments are conditioned on the executive executing (and not revoking) a general release of claims. Full amendment texts will be filed in the next Form 10‑Q.

Why It Matters

• These amendments increase the company’s contractual obligations to top executives on certain terminations and around a change in control, which can affect future cash outflows and compensation expense when severance is triggered.
• The revised equity vesting rules provide executives greater near‑term protection of equity value on qualifying terminations (accelerated RSU vesting and prorated PSU treatment), which can influence retention and decision‑making around leadership continuity during potential corporate events.
• Investors should note these are contractual changes (not immediate payments) and the company will disclose the full agreements in its next quarterly filing.